|
|
|
|
| Symbol(s): |
OPTR |
| Date: |
13-May-13 |
| Author: |
Hunter Orr |
| Contributor: |
Alpha Street Research |
| Title: |
OPTR - Optimer Pharmaceuticals Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report |
| Document Size: |
9 pages |
| Price: |
$24 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $24. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Optimer Pharmaceuticals, Inc. discovers, develops, and commercializes anti infective products. Optimer's initial development efforts address products that treat gastrointestinal infections (GI), and related diseases, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient...
| | |
|
|
